卵巢组织冻存移植安全性的研究进展  

Research progresses in the safety of cryopreserved ovarian tissue transplantation

作　　者：程姣姣 阮祥燕[1] 杜娟[1] 金凤羽[1] 李扬璐[1] 谷牧青[1] Cheng Jiaojiao;Ruan Xiangyan;Du Juan;Jin Fengyu;Li Yanglu;Gu Muqing(Department of Gynecological Endocrinology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100026,China)

机构地区：[1]首都医科大学附属北京妇产医院内分泌科,北京100026

出　　处：《首都医科大学学报》2021年第4期505-510,共6页Journal of Capital Medical University

基　　金：北京市自然科学基金(7202047);首都卫生发展科研专项(2020-2-2112);北京市医院管理局“登峰”计划专项经费资助(DFL20181401)。

摘　　要：卵巢组织冻存与移植技术是一项成熟的生育力保护技术,然而,有些癌症类型中,冻存的卵巢组织中可能存在恶性细胞,因此在患者疾病痊愈后不建议进行卵巢组织移植。为了恢复这些患者的生育力,目前主要采用两种策略:1)人工卵巢移植,其主要目的是模拟卵巢天然器官;2)体外培养卵巢组织:将分离的卵泡体外培养成熟至可受精的卵母细胞。本文主要综述冻存卵巢组织移植安全性及避免携癌风险高的卵巢组织移植导致疾病复发的新方法的研究进展。Ovarian tissue cryopreservation and transplantation is an established fertility preservation technique.In some types of cancer,however there may be malignant cells in the frozen ovarian tissue,so ovarian tissue transplantation is not recommended for the patient who has recovered from the disease.In order to restore the fertility of these patients,there are two main strategies:transplantable artificial ovaries,to simulate the natural organs of the ovary and isolated follicles matured in vitro into fertilizable oocytes.This article mainly reviewed the research progresses in the safety of cryopreserved ovarian tissue transplantation and the new methods to avoid disease recurrence caused by ovarian tissue transplantation with high risk of carrying malignant cells.

关 键 词：卵巢组织冻存 卵巢组织移植 生育力保护 移植安全性 人工卵巢 窦前卵泡 体外培养 

分 类 号：R711.75[医药卫生—妇产科学]